Our study shows that, unlike in NSCLC, IHC is an insufficient tool for the diagnosis of ALK rearrangement in neuroendocrine tumors of the lung due to the high prevalence of false-positive cases and low specificity. This evidence concerns the gene ALK and non-small cell lung carcinoma.